Sean Ekins 5/25/22 Sean Ekins 5/25/22

Global Collaboration Demonstrates Pyronaridine Is Active Against COVID-19 In An Animal Model

Raleigh – Collaborations Pharmaceuticals, Inc. and international collaborators publish paper on pyronaridine and its protection against infection with SARS-CoV-2.

Sean Ekins 5/23/22 Sean Ekins 5/23/22

Collaborations Pharmaceuticals, Inc. Announces Major Updates To 2022 Pipeline

Collaborations Pharmaceuticals, Inc. (CPI) announced major updates to their drug discovery research and development pipeline aided by machine learning software.

Sean Ekins 4/13/22 Sean Ekins 4/13/22

Collaborations Pharmaceuticals, Inc. Awarded An SBIR From NIH/NIDA To Develop Drugs For Opioid Abuse Treatment

Raleigh – The National Institute on Drug Abuse has awarded a $256,220 SBIR grant to Collaborations Pharmaceuticals, Inc.

Sean Ekins 4/12/22 Sean Ekins 4/12/22

Collaborations Pharmaceuticals, Inc. Awarded A Matching Grant From One North Carolina Small Business Program

Raleigh – The North Carolina Department of Commerce has awarded a matching award totaling $75,000 to Collaborations Pharmaceuticals, Inc. to support cutting edge science.

Sean Ekins 3/24/22 Sean Ekins 3/24/22

Stepan Company Has Licensed Collaborations Pharmaceuticals, Inc. MegaTox Machine Learning Software

Raleigh – Collaborations Pharmaceuticals, Inc. (CPI) announced today that they have entered into an agreement with Stepan Company to license CPI’s MegaTox® machine learning software for predicting toxicology properties to aid their decision making and regulatory processes.